Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3

Xi-lin Dong; Ying Gong; Zhen-zhen Chen; Ya-juan Wang

doi:10.1007/s11655-013-1335-0

Your Location：

Home >

Browse articles >

Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3

Updated：2021-08-27

- Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3
- Chinese Journal of Integrative Medicine Vol. 20, Issue 4, Pages: 286-291(2014)
- Affiliations：
  
  1. Department of Respiratory, the Second Affiliated Hospital, College of Medicine of Xi’an Jiaotong University,Xi’an,China
  2. Department of Pharmacy, the Fourth People’s, Hospital of Ji’nan City, Ji’nan,China
  3. Department of Respiratory, Zibo Central Hospital,Shandong Province,Zibo,China
- Author bio：
- Funds：
  
  Supported by the Project of Science and Technology Development in Shaanxi Province of China (No. 2008KG10-01)
- DOI：10.1007/s11655-013-1335-0
  CLC：
- Published：2014，
  
  Published Online：23 October 2013，
Scan for full text
Dong, Xl., Gong, Y., Chen, Zz. et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3., Chin. J. Integr. Med. 20, 286–291 (2014). https://doi.org/10.1007/s11655-013-1335-0

Xi-lin Dong, Ying Gong, Zhen-zhen Chen, et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3. [J]. Chinese Journal of Integrative Medicine 20(4):286-291(2014)
Dong, Xl., Gong, Y., Chen, Zz. et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3., Chin. J. Integr. Med. 20, 286–291 (2014). https://doi.org/10.1007/s11655-013-1335-0 DOI：

Xi-lin Dong, Ying Gong, Zhen-zhen Chen, et al. Delisheng Injection (得力生注射液), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3. [J]. Chinese Journal of Integrative Medicine 20(4):286-291(2014) DOI： 10.1007/s11655-013-1335-0.

摘要

To investigate the effect of Delisheng Injection (得力生注射液

DLS)

a Chinese medicinal compound

DLS combined with cis-platinum (DDP)

an active agent used in lung cancer chemotherapy

on a human highly metastatic giant lung carcinoma cell line PGCL3. The suspended PGCL3 cells at 105 /mL cultured in 96-well tissue culture plates were divided into 4 groups: DLS treatment group (2 μL/mL

5 μL/mL

10 μL/mL

25 μL/mL)

DDP treatment group (1 μg/mL

2 μg/mL

5 μg/mL

15 μg/mL)

combined DLS with DDP treatment group (DLS:DDP 2 μL/mL:1 μg/mL

5 μL/mL:2 μg/mL

10 μL/mL:5 μg/mL

25 μL/mL:15 μg/mL) and a control group. The cytotoxicity of DLS with different concentrations (2 μL/mL

5 μL/mL

10 μL/mL

25 μL/mL) on PGCL3 cells was determined by 3-(4

5)-dimethylthiahiazo(-z-y1)-3

5-di-phenytetrazoliumromide (MTT) assay. Effect of DLS on adhesion of PGCL-3 cells was tested by cell-matrigel adhesion assay. Chemotactic movement model of transwell camerula was used to determine the effect of DLS on invasion and migration of PGCL-3 cells. Compared with the control group

DLS (2 μL/mL

5 μL/mL

10 μL/mL

25 μL/mL) could significantly decrease cell proliferation

adhesion

invasion and migration abilities (P <0.05). Cell adhesion

invasion and migration abilities were significantly decreased after combination treatment of DLS:DDP (2 μL/mL:1 μg/mL

5 μL/mL:2 μg/mL

10 μL/mL:5 μg/mL

25 μL/mL:15 μg/mL) compared with DDP single-agent treatment (1 μg/mL

2 μg/mL

5 μg/mL

15 μg/mL

P<0.05)

respectively. DLS single-agent has a satisfying inhibition effect in PGCL3 cell line and DLS might enhance the inhibition effect of DDP on cancer metastasis. Our research provided a experimental basis about the treatment on highly metastatic lung caner.

Abstract

To investigate the effect of Delisheng Injection (得力生注射液

DLS)

a Chinese medicinal compound

DLS combined with cis-platinum (DDP)

an active agent used in lung cancer chemotherapy

5 μL/mL

10 μL/mL

25 μL/mL)

DDP treatment group (1 μg/mL

2 μg/mL

5 μg/mL

15 μg/mL)

combined DLS with DDP treatment group (DLS:DDP 2 μL/mL:1 μg/mL

5 μL/mL:2 μg/mL

10 μL/mL:5 μg/mL

25 μL/mL:15 μg/mL) and a control group. The cytotoxicity of DLS with different concentrations (2 μL/mL

5 μL/mL

10 μL/mL

25 μL/mL) on PGCL3 cells was determined by 3-(4

5)-dimethylthiahiazo(-z-y1)-3

DLS (2 μL/mL

5 μL/mL

10 μL/mL

25 μL/mL) could significantly decrease cell proliferation

adhesion

invasion and migration abilities (P <0.05). Cell adhesion

invasion and migration abilities were significantly decreased after combination treatment of DLS:DDP (2 μL/mL:1 μg/mL

5 μL/mL:2 μg/mL

10 μL/mL:5 μg/mL

25 μL/mL:15 μg/mL) compared with DDP single-agent treatment (1 μg/mL

2 μg/mL

5 μg/mL

15 μg/mL

P<0.05)

关键词

lung cancerdelishengcis-platinumPGCL3

Keywords

lung cancerdelishengcis-platinumPGCL3

references

Crino L, Foglietta J, Hamzaj A. Lung cancer. Thorac Oncol 2007;5(Supp1):S24–S26.

Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;1:243–250.

American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997;15:2996–3108.

Zou ML, Li QY, Zuo FX. Efficacy of Delisheng combined with TP chemotherapy in treatment of advanced non-small cell lung cancer. J Modern Oncol (Chin) 2009;17:274–275.

Zhao D, Liu XJ, Xie Q, Huang ZP, Zou BX, Ge YB. Intensity-modulated radiation combined with Delisheng Injection for naspharyngeal carcinoma. J South Med Univ (Chin) 2006;26:874–875.

Cui J, Nan KJ, Tian T, Guo YH, Zhao N, Wang L. Chinese medicinal compound Delisheng has satisfactory antitumor activity, and is associated with up-regulation of endostatin in hunman hepatocellular carcinoma cell line HepG2 in three-dimensional culture. World J Gastroenterol 2007;13:5432–5439.

Lu CX, Nan KJ, Nie YL, Han YN, Jiao M. Delisheng, a Chinese medicine compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways. Mol Biol Rep 2010;37:3407–3412.

Wang J, Wang ZL, Zhu YJ, Guo ZJ, Li LY. A study of lung cancer cell apoptosis induced by V16 and Delisheng. Chin J Integr Tradit West Med (Chin) 1998;37:532–535.

Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010;29:465–482.

Liotta LA. Tumor invasion and metastasis role of the extracellar matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1–7.

Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippiteli M. Bcl-2 overexpression enhances NF-kB activity and induces MMP-9 transcription in human MCF7ADR breast cancer cells. Int J Cancer 2000;86:188–196.

Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008;27:679–690.

Chang YS, Seo EK, Gyllenhaal C, Block KI. Panax ginseng: a role in cancer therapy? Block Integr Cancer Ther 2003;2:13–33.

Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgendependent and- independent human prostate cancer cells. Cancer Sci 2008;98:2467–2476.

Wang JY, Jin Y, Xu ZY, Zheng Z, Wan S. Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in 549 cells. Exp Biol Med 2009;234:566–572.

McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum based chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. J Clin Oncol 2006;24:419–430.

FULL TEXT LINK

More>

Views

855

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Systematic review of β-Elemene injection as adjunctive treatment for lung cancer

Objectified study on tongue images of patients with lung cancer of different syndromes

Anti-fungal test of composite agastache lotion on seven pathogenic fungi and its clinical application

Dynamic observation and clinical assessment of integrated traditional chinese and western medicine on interleukin-2 system, T Cell and erythrocyte immune system in patients of lung cancer

Effects of 24 Chinese medicinal herbs on nucleic acid, protein and cell cycle of human lung adenocarcinoma cells

Related Author

No data

Related Institution

Biomedicine and Health Research Center, Hangzhou Normal University

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University

Institute of Basic Research in Chinical Medicine, China Academy of Chinese Medical Sciences

Guang’anmen Hospital, China Academy of Chinese Medical Sciences

School of Public Health and Family Medicine, Capital Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰